X Facebook LinkedIn WhatsApp Press Releases (-) Any 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 Reset 2015 October 21, 2015 arGEN-X Completes First Dosing of ARGX-113 for Severe Autoimmune Disorders February 22, 2015 arGEN-X’ Partner RuiYi, Inc. Announces First Human Dosing of Gerilimzumab, A Novel SIMPLE Antibody™ Against IL-6 August 24, 2015 arGEN-X Announces Half-Year Results For 2015 August 18, 2015 arGEN-X to Host Conference Call & Webcast to Report Half-Year Results on 26 August 2015 August 6, 2015 arGEN-X to Present at Wedbush PacGrow Healthcare Conference July 29, 2015 arGEN-X and University of Bern enter into license agreement to develop ARGX-110-based combination therapies for treatment-resistant cancers July 14, 2015 Change to the Board of Directors June 17, 2015 Preliminary Phase I results of ARGX-110 in patients with T-cell lymphomas presented at ICML May 31, 2015 arGEN-X to Present at Jefferies 2015 Global Healthcare Conference on Tuesday, 2 June at 8:00am EDT May 28, 2015 arGEN-X Presents Preliminary Efficacy and Expanded Safety Data from Phase I Trial of ARGX-111 at ASCO May 20, 2015 arGEN-X and LEO Pharma Enter into Alliance to Develop Antibody-based Treatments for Skin Conditions May 18, 2015 arGEN-X Awarded €1.5 Million IWT Grant to Advance the Application of NHance® Fc Modifications in Therapeutic Antibodies Pagination First page « First Previous page ‹ Previous … Page 22 Page 23 Page 24 Page 25 Current page 26 Page 27 Page 28 Page 29 Page 30 … Next page Next › Last page Last »